Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Sermorelin vs. CJC-1295 | A Comprehensive Comparison

Interested in a detailed comparison of sermorelin vs. CJC-1295 based on clinical data? Then this is the right place. In this detailed guide, we'll delve into both of these two powerful research peptides, shedding light on their potential advantages in areas su

By Recovery & Performance Peptides Editorial Team

Interested in a detailed comparison of sermorelin vs. CJC-1295 based on clinical data? Then this is the right place.

In this detailed guide, we'll delve into both of these two powerful research peptides, shedding light on their potential advantages in areas such as:

Growth hormone stimulation

Muscle growth

Cellular repair

Abdominal fat loss

Continue reading to uncover up-to-date clinical findings on the two peptides’ mechanisms, structural differences, potential side effects, and more.

Additionally, we'll introduce our top-rated source for research peptides, including both sermorelin and CJC-1295.

Buy research peptides from our top-rated vendor...

Disclaimer: Peptides.org contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Likewise, any published information relative to the dosing and administration of reference materials is made available strictly for reference and shall not be construed to encourage the self-administration or any human use of said reference materials. Peptides.org makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. Peptides.org makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.

What is Sermorelin?

Sermorelin, known by its chemical name as GRF 1-29, is a synthetic analog of growth hormone-releasing hormone (GHRH). Comprising 29 amino acids, sermorelin is a truncated and amidated (at the C-terminus) version of endogenous GHRH, itself made up of 44 amino acids [1, 2].

Specifically, sermorelin is the smallest GHRH fragment and possesses the bioactive sequence responsible for evoking the secretion of growth hormone (GH) from the anterior pituitary gland [1, 2].

The peptide works to stimulate the release of GH in a manner similar to endogenous GHRH. This release of GH plays a crucial role in growth, metabolism, and cellular proliferation.

Sermorelin was first patented and marketed in 1990 by German pharmaceutical company Merck Serono (EMD Serono in the United States and Canada) under the brand name Geref. It was formulated for two different indications. The two formulations were [3, 4]:

0.05mg sermorelin acetate for intravenous injection, approved in 1990 by the United States Food and Drug Administration (FDA) as a diagnostic agent for growth hormone deficiency (GHD).

0.5 and 1mg sermorelin acetate for subcutaneous injection, which was FDA approved in 1997 for therapy in children with idiopathic short stature.

The peptide has also been extensively studied for its potential effects in adults, administered either as once-daily or twice-daily subcutaneous injection [5].

EMD Serono discontinued the product and its FDA approval was withdrawn due to difficulties in the manufacturing and marketing processes unrelated to its safety or effectiveness [4, 6].

The peptide is currently available for educational and experimental purposes and may be legally purchased by qualified professionals for laboratory experimentation.

What is CJC-1295?

CJC-1295, also known as modified GRF 1-29 with DAC or DAC:GRF, is a modified version of sermorelin. The primary goal of these modifications was to improve the half-life of sermorelin, which is about 10 minutes [6].

The amino acid structure of GRF 1-29 was modified at four different positions to improve its resistance to hydrolysis and oxidation. Importantly, L-alanine was replaced with D-alanine at the 2nd position, which increased the peptide’s resistance to an enzyme called dipeptidyl peptidase-4 (DPP-4). DPP-4 is a major enzyme responsible for deactivating peptides [7].

Due to these modifications, CJC-1295 no DAC is also known as tetrasubstituted or modified GRF 1-29, and has a three-fold longer half-life compared to sermorelin.

In addition, CJC-1295 can also be modified with the drug affinity complex (DAC), which improves the molecule's pharmacokinetics. The attachment is also known as N-epsilon-3-maleimidopropionamide and is attached to the N-terminus of the peptide.

With this complex, CJC-1295 DAC has increased affinity to plasma proteins, prolonging its half-life to about eight days [8].

CJC-1295 was developed by the Canadian company ConjuChem Biotechnologies as a potential treatment for lipodystrophy in HIV/AIDS patients.

Individuals with lipodystrophy have abnormal body fat distribution, such as depleted fat levels in the face and the extremities, while also having increased amounts of abdominal and intraorgan (visceral) fat. It occurs in HIV/AIDS as a side effect of antiviral treatment.

CJC-1295 reached phase-2 trials, but experiments were halted due to a myocardial infarction in one of the HIV/AIDS patients treated after the 11th CJC-1295 dose [9, 10].

While it was ruled unlikely that the event was related to the peptide, the investigators decided to halt any future trials. Thus, the peptide has not been approved for human use and is currently available for research use in laboratory settings.

CJC-1295 vs. Sermorelin | Comprehensive Comparison

Both CJC-1295 and sermorelin are 29 amino acid peptide analogs of GHRH, activating the corresponding receptors in the anterior pituitary gland to stimulate the synthesis of GH.

Yet, the two peptides differ significantly in their half-life, resulting in different GH responses following administration.

Physiological GH secretion occurs in pulses, which can reach about 10ng/ml in men and 14ng/ml in women [11]. Both CJC-1295 and sermorelin appear to increase GH levels produced during pulses without causing the hormone to reach supraphysiological levels. Pulse frequency remains unaffected.

Here are some of the most interesting studies regarding the GH-boosting potential of each peptide:

CJC-1295 has been administered to healthy young and middle-aged study volunteers as a single dose, ranging between 30mcg/kg and 250mcg/kg of body weight. The peptide increased total GH levels while preserving pulsatile secretion, and peak levels remained within physiological limits. A 60mcg/kg dose led to a roughly 150% increase in mean GH levels.

A single 250mcg/kg dose led to an over 300% increase in GH AUC. The 60mcg/kg dose was also tested as a biweekly dosage (applied twice in 14 days), and the protocol led to a sustained increase in mean GH levels by the 28th day [12].

CJC-1295, injected as a single injection in another study, was effective at increasing GH even one week after application in 20-40 y.o. men. Study authors reported that the mean (12-hour) GH levels, measured seven days after peptide injection, were 46% higher than mean pretreatment levels [13].

Sermorelin was studied over six weeks in 11 elderly males receiving 2mg/daily as subcutaneous injections. This treatment boosted the volunteers’ mean GH levels by 82%, as indicated by AUC measurements. Elevated GH concentrations remained for about two hours after each injection [14].

Sermorelin as a twice-daily injection (morning and evening) for four weeks led to a significant increase in GH levels in young and elderly men. More specifically, 2mg/daily sermorelin helped elderly subjects achieve a 64% increase in GH AUC, attaining GH levels similar to those in young, untreated, healthy males. The 4-hour GH AUC was higher following the evening injection compared to the morning injection [15].

Benefits of Sermorelin

Sermorelin exerts its benefits by increasing GH synthesis. For example, higher GH levels increase lipolysis (the release of fat from fat cells).

The hormone primarily targets the fatty tissues around the abdomen; therefore, higher GH levels may help to significantly reduce visceral and belly fat [16]. Unfortunately, there are no clinical trials beyond 16 weeks of sermorelin therapy, and the data do not show any significant fat loss within this timeframe [5].

In addition, GH stimulates the production of an anabolic hormone called insulin-like growth factor-1 (IGF-1), which mediates GH's anabolic effects, such as the potential for lean body mass increase.

By upregulating GH production, sermorelin also leads to an increase in IGF-1 levels. The longest and most notable clinical trial on sermorelin's anabolic potential lasted 16 weeks and included 19 elderly subjects receiving 10mcg/daily [17].

Here are the most notable findings as reported by the researchers [17]:

Increased IGF-1 levels. The peptide led to a 107% increase in GH AUC and a 28% increase in mean IGF-1 levels in the treated men. The GH increases in women were slightly lower, equal to +70% for GH AUC and a 27% increase in IGF-1 levels. These levels are comparable to those observed in healthy young adults.

Lean mass gains. The male subjects in the study gained +2.78lb (+1.26kg) lean mass during the study period. Yet, there was no effect on the female participants. Nevertheless, nitrogen retention was increased in both sexes, indicating the peptide’s anabolic potential.

Skin cell proliferation. Skin thickness increased in both the male and female subjects. This indicates that the increase in GH was accompanied by increased proliferation of collagen-producing skin cells such as fibroblasts.

Benefits of CJC-1295

Currently, only one clinical trial has administered CJC-1295 for longer than 14 days. This was the aforementioned 12-week trial in HIV/AIDS patients with lipodystrophy that was discontinued, and its data were never published [9, 10].

Shorter trials, which have lasted up to two weeks, are of insufficient length to report any effects of CJC-1295 on weight loss or muscle mass.

Instead, we turn to preclinical studies employing CJC-1295 in GHD mice. GHD is known to cause growth failure, low lean mass, and increased abdominal obesity.

Here are the most notable results reported by one such preclinical study in mice with artificially induced GHD due to genetic modifications and lack of GHRH synthesis [18]:

Improved growth and lean body weight. Test animals with GHD had about 20% lower lean body weight than the norm and could not reach normal body length or weight. Daily administration of CJC-1295 led to normalization of lean body weight.

Body fat and visceral fat reduction. Test animals with GHD suffered from visceral obesity, which increases the risk of metabolic conditions. The administration of CJC-1295 normalized visceral fat levels.

It’s important to note that preclinical study results do not reflect potential outcomes in clinical settings.

Sermorelin Side Effects

The FDA previously approved sermorelin for use in children with growth failure based on safety trials. The studies reported mild side effects, such as facial flushing and injection site reactions [19].

Studies in adults also indicate the peptide’s safety, primarily reporting injection site reactions such as [14, 15]:

Pain

Swelling

Inflammation

Induration

Bleeding

A 16-week sermorelin study also observed temporary hyperlipidemia in some participants, possibly due to increased fat release from adipose cells [17].

It’s crucial to mention that subjects with oncological conditions should be excluded from sermorelin research, as elevated GH levels could promote cell proliferation and disease progression.

CJC-1295 Side Effects

Similar to the safety data on sermorelin, the most commonly reported side effects from CJC-1295 therapy are injection site reactions.

In addition, mild to moderate adverse reactions reported include [12, 13]:

Increased heart rate

Headaches

Diarrhea

Nausea

Abdominal pain

Facial flushing

It’s important to note that the FDA has not reviewed the peptide for human use, and its safety has not been tested in large-scale clinical studies. The only long-term trial was discontinued due to a case of fatal myocardial infarction, deemed unrelated to CJC-1295 itself [9].

Similar to sermorelin and other peptides that upregulate GH synthesis, CJC-1295 should not be administered to subjects with oncological conditions.

CJC-1295 vs. Sermorelin | Dosage Calculator

CJC-1295 and sermorelin have both been administered as subcutaneous injections in research settings.

However, the dosage regimes for the two compounds differ significantly, primarily due to the sizable discrepancy between their respective half-lives.

The proper dosage of CJC-1295 and sermorelin depends on research goals and objectives. Below, we outline reference dosing regimes for each compound, as applied in available scientific publications.

Reference Sermorelin Dosing Protocol

Available clinical data reveal that sermorelin has been administered in daily doses ranging from 10 to 25mcg per kg of body weight. Thus, most trials have used daily doses of sermorelin 1-2mg subcutaneously for up to 16 weeks [5].

In addition, the peptide has been administered as either a single or twice-daily injection. The data reveal that evening injections are more effective for increasing GH AUC than morning injections [15].

Thus, sermorelin is best administered in the evening when following a once-daily protocol or early in the morning and before bed when following a twice-daily administration protocol.

Based on these data, experts recommend initiating studies with a conservative daily dosage of 0.5mg and before increasing to up to 1mg and 2mg daily, depending on the subject's tolerance and response.

Here is a sample dosing regimen for sermorelin based on these guidelines:

Daily Dose: 0.5mg/daily via subcutaneous injection.

Frequency: Once or twice daily.

Study Duration: Daily, up to 16 weeks.

Notes: Rotate injection sites with each injection. Do not exceed a daily sermorelin dosage of 2mg.

Reference CJC-1295 DAC Dosing Protocol

According to available clinical data, CJC-1295 DAC has been administered effectively in doses ranging between 30-60mcg per kilogram of body weight per week [12].

The article linked above also covers a CJC-1295 No DAC dosing protocol.

Based on the data, here is a sample CJC-1295 DAC dosing protocol:

Dose per injection: 30-60mcg/kg of body weight per week.

Frequency: Administer once weekly, subcutaneously.

Study Duration: Up to 12 weeks.

Notes: Rotate injection sites after each injection.

Where to Buy HGH Peptides Online? | 2024 Edition

Researchers and laboratory professionals seeking sermorelin and/or CJC-1295 for their studies are advised to buy these compounds strictly from the following vetted sources.

Here's our top recommendations to do just that:

Limitless Life

At Peptides.org, we highly recommend Limitless Life to researchers who are ready to source HGH peptides for their research studies. Limitless Life has demonstrated an outstanding commitment to product quality, safe and responsible peptide distribution, and customer service.

Here are a few of the many reasons we like Limitless Life:

Independent Verification of Peptide Purity: Limitless Life backs up their quality standards by ensuring that each batch of peptides is independently tested by a third-party lab.

Dedication to Safety For All: Limitless Life demonstrates their dedication to the safe and responsible distribution of research peptides by emphasizing repeatedly on their website that peptides are intended for research use only.

Reputable and Trustworthy: Limitless Life has an excellent reputation in the larger research peptide community because they are truly dedicated to product quality and customer satisfaction.

Easy-to-Access Service: No matter where in the world a researcher lives, their issues will be addressed quickly because Limitless Life customer service is available 7 days per week.

Limitless Life offers CJC-1295 No DAC and CJC-1295 No DAC + Ipamorelin.

Buy research peptides from Triumphant Labs, a top-rated vendor...

Xcel Peptides

Here's why Xcel Peptides stands out as the premier choice for acquiring research-grade sermorelin and CJC-1295:

US-Based Production: Xcel Peptides collaborates with domestic manufacturers following Good Manufacturing Practices (GMP) standards.

Assured Purity: With a commitment to peptide quality, Xcel Peptides provides sermorelin and CJC-1295 that meet a 99% purity standard.

Efficient Shipping: Prioritizing convenience, Xcel Peptides offers a seamless online shopping experience complemented by swift and dependable shipping. They also waive shipping fees for domestic orders exceeding $200.

Selecting a trustworthy supplier like Xcel Peptides is paramount to the safety and success of research. Their unwavering dedication to product quality, purity, and customer satisfaction makes them a great choice for buying sermorelin and CJC-1295 online.

Buy research peptides from Polaris Peptides today...

Bacteriostatic Water and Research Peptides

A well-organized lab is essential for effective and safe research on peptides like sermorelin and CJC-1295.

Researchers need to have all the right equipment, including insulin syringes, bacteriostatic water, and sterile vials. Yet, finding top-notch supplies from online vendors can be challenging.

This is why we recommend a trusted online provider that simplifies this process. Click here to learn more.

CJC-1295 vs. Sermorelin | Overall

When comparing sermorelin vs. CJC-1295, it's important to note that both peptides have been shown to reliably stimulate increased production of GH in the anterior pituitary gland.

The two peptides also have similar structures, and CJC-1295 can be viewed as a modified version of sermorelin. The main difference between the two peptides is in their pharmacokinetics, as CJC-1295 DAC has an extended half-life of up to 8 days.

As a result, CJC-1295 also appears to have a greater GH and IGF-1 stimulating capacity, as measured in test subjects. On the other hand, sermorelin is better researched and has even held FDA approval for use in children with growth hormone deficiency.

Qualified professionals looking to test sermorelin or CJC-1295 firsthand are advised to obtain either compound from a trusted source like this one.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Clinical Dosing Protocols and Administration Guidelines

Establishing appropriate dosing protocols for CJC-1295 requires consideration of the peptide's extended pharmacokinetic profile, individual patient characteristics, therapeutic objectives, and safety parameters. Unlike traditional pharmacologic agents with established dosing guidelines, peptide secretagogues often require individualized protocol development based on biomarker monitoring and clinical response assessment.
STORAGE

Specifications, Handling, and Storage

Before incorporating CJC-1295/Isa 5/5mg research peptide into a new study, teams typically review specifications such as the amount per vial, nominal purity percentage, and any notes on recommended storage conditions. These details are important because they determine how stock solutions are prepared, how frequently they should be remade, and what type of containers are appropriate for short-term and long-term storage. Many laboratories prefer to log each vial into an inventory system as soon as it arrives. A typical workflow might include assigning an internal inventory number, scanning the barcode on the shipping label, and recording the lot number from the vial label. Doing this at the receiving bench ensures that no vial is ever used without a clear record of its origin. It also makes it easier to rotate stock so that older vials are used first while newer vials remain in deep storage. Storage practices vary between institutions, but most research teams using CJC-1295/Isa 5/5mg research peptide rely on designated refrigerators or freezers that are reserved for high-value reagents. Temperature logs, access control, and regular maintenance of refrigeration equipment are simple steps that help protect peptide integrity. Clear “research use only” notation further reinforces that the materials are not intended for any type of administration or diagnostic procedure. Supplemental images showcasing multiple vials together are often used in presentations, internal training docume…
02

Question drills

Open a question for its connected answer.

01What If My Reconstituted CJC-1295 Was Left Out of the Fridge Overnight?+

If the solution was at room temperature (18–25°C) for fewer than 24 hours, refrigerate it immediately and continue use. Short-term ambient exposure causes minimal degradation. Beyond 24 hours or if the temperature exceeded 30°C, discard the vial. Denatured CJC-1295 cannot be visually identified. The solution remains clear even after the peptide structure has collapsed. Using compromised peptide wastes the injection and produces no therapeutic effect. Unreconstituted lyophilised powder tolerates brief temperature excursions better than reconstituted solution, but both should be stored according to protocol without exception.

SOURCE / realpeptides.co ↗
02What If My CJC-1295 Vial Was Left Out of the Fridge Overnight?+

Discard it. Lyophilized CJC-1295 exposed to room temperature (20–25°C) for 8+ hours has likely undergone enough thermal stress to initiate aggregation, and reconstituted peptide left unrefrigerated overnight has lost 40–60% potency through hydrolysis and oxidation. The peptide may still appear clear, but receptor binding affinity is compromised. Peptide stability studies show that even a single temperature excursion above 15°C for six hours reduces bioactivity measurably. The damage is irreversible and compounding. Don't attempt to salvage it by re-refrigerating.

SOURCE / realpeptides.co ↗
03What If I Inject CJC-1295 at Hour 18 of a 24-Hour Fast?+

Inject as planned. The peptide won't break your fast. CJC-1295 stimulates growth hormone release, which will elevate lipolysis and maintain the metabolic benefits of fasting. If autophagy is your primary goal, this timing may modestly reduce autophagic flux during hours 18–24 due to IGF-1 elevation, but the effect is minor compared to amino acid or insulin exposure. For fat loss, this is optimal timing.

SOURCE / realpeptides.co ↗
04What If I'm Already Taking Other Peptides Like BPC-157 or TB-500?+

Stacking peptides is common in research contexts, though direct interaction studies don't exist. BPC-157 and TB-500 act through different pathways (angiogenesis, actin regulation, inflammatory modulation) than CJC-1295's GH-IGF-1 axis. The mechanisms are theoretically complementary rather than redundant. If you're considering multi-peptide protocols, staging them (e.g., BPC-157 during weeks 1–4, CJC-1295 during weeks 3–12) may reduce the number of simultaneous variables and allow clearer assessment of individual contributions.

SOURCE / realpeptides.co ↗
05What If I Accidentally Dosed CJC-1295 Right After a Large Meal?+

The dose isn't wasted, but efficacy is significantly reduced. Elevated insulin will suppress GH secretion for 2–3 hours post-meal, meaning the peptide is present but your pituitary response is blunted. Don't redose. CJC-1295's long half-life means the peptide remains active for days. Simply return to proper fasting protocol for your next scheduled dose. One mistimed injection across a 12-week research cycle has minimal cumulative impact.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

The Mechanistic Truth About CJC-1295 and Bone Health Research

Here's the honest answer: CJC-1295 is not a bone drug. It's a growth hormone secretagogue with downstream effects on bone metabolism that are entirely mediated through the GH/IGF-1 axis. Strip away the GH pathway. Block the IGF-1 receptor, use CJC-1295 in hypophysectomized animals, administer it in populations with GH receptor mutations. And the bone effects disappear completely. This distinction matters because it defines the limits of research application. CJC-1295 cannot directly rescue osteoblast dysfunction caused by non-GH-mediated pathways (e.g., glucocorticoid-induced osteoporosis, primary hyperparathyroidism, Paget's disease). Its utility is confined to conditions where GH insufficiency is the primary or contributing driver of bone loss. The second truth: the evidence base for using CJC-1295 in bone health research is thin. Fewer than a dozen peer-reviewed studies exist, none with fracture endpoints, and the longest human trial ran 12 weeks. The surrogate marker data (IGF-1, P1NP, BMD) are promising but not definitive. Promising means hypothesis-generating, not practice-changing. For researchers designing protocols, this means CJC-1295 is best positioned as a mechanistic tool for studying GH pathway biology in bone. Not as a therapeutic candidate ready for Phase III fracture prevention trials. The final truth: peptide research-grade purity matters more in bone studies than in many other applications because bone remodeling is a multi-month process. Impurities, degradation products, or inconsistent dosing caused by poor reconstitution practices will introduce noise that swamps signal in studies measuring slow endpoints like BMD or histomorphometry. Every batch should be third-party tested for purity (≥98% by HPLC), endotoxin levels (<5 EU/mg), and peptide content verification. Our dedication to quality extends across our entire product line. You can explore the potential of other research compounds like Dihexa and see how our commitment to exact amino-acid sequencing and small-batch synthesis translates into lab reliability across diverse biological systems. Using CJC-1295 for bone health research evidence requires acknowledging what exists and what doesn't. The mechanistic rationale is sound, the preclinical data are compelling in the right models, and the human marker studies are consistent. But the gap between bone turnover markers at 12 weeks and fracture risk reduction at 5 years is enormous. And that gap has not been bridged. CJC-1295 remains a research tool, not a validated therapeutic, and research design should reflect that reality with appropriate endpoints, control groups, and mechanistic biomarkers that link observed effects to the GH/IGF-1 pathway explicitly. If the pellets concern you, raise it before installation. Specifying a different infill costs nothing extra upfront and matters across a 15-year turf lifespan. For bone research protocols, the equivalent principle applies: specify your research question, your population's baseline GH status, and your mechanistic biomarkers before selecting CJC-1295 as the intervention. The compound works. But only in the right context, and only when the biology aligns with what the GH/IGF-1 pathway can actually modulate.

RESEARCH

CJC-1295: How the GHRH Analog Works, and What Research Shows

CJC-1295: How the GHRH Analog Works, and What Research Shows CJC-1295 is one of the most referenced growth-hormone-releasing peptides in the research literature, and one of the most frequently confused. Part of that confusion comes from two closely related versions of the molecule that get used interchangeably online but behave very differently. This overview walks through what CJC-1295 actually is, how it's understood to work, the DAC-versus-no-DAC distinction that trips people up, and how to evaluate a research-grade preparation. This article is for educational and research reference only. It is not medical advice, and Element materials are sold for laboratory and research use. What CJC-1295 is CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). The body's own GHRH is a signaling peptide released by the hypothalamus that tells the pituitary gland to secrete growth hormone. It's a short-lived molecule by design — it acts in pulses and is broken down quickly. CJC-1295 is built on the first 29 amino acids of GHRH — the fragment that carries the biological activity — with targeted amino-acid substitutions that protect it from the enzymes that normally degrade natural GHRH. The result is a GHRH-like molecule that resists breakdown far longer than the native hormone. That stability is the entire point of the modification, and it's the property most of the research interest is built on. The DAC vs no-DAC distinction This is the single most important thing to understand, because the two forms are often sold under the same "CJC-1295" name: CJC-1295 with DAC carries a Drug Affinity Complex — a chemical group that lets the peptide bind reversibly to albumin, a protein that circulates in blood. Tethered to albumin, the molecule persists far longer, which in research settings translates to a substantially extended half-life measured in days rather than minutes. CJC-1295 without DAC — more accurately called modified GRF (1-29) or "mod GRF 1-29" — keeps the stabilizing substitutions but omits the albumin-binding complex. It's still far more durable than natural GHRH, but its action is shorter and more pulse-like, closer to how endogenous GHRH behaves. The distinction matters because the two forms produce different pharmacological profiles in study models: DAC creates a sustained elevation, while no-DAC produces a sharper, more transient signal. Researchers choose between them based on which profile a given experiment calls for. When you see "CJC-1295," always confirm which version a supplier is actually shipping — the certificate of analysis should specify it. How it's understood to work CJC-1295 acts on the GHRH receptor on pituitary cells. By mimicking GHRH but resisting degradation, it prolongs the signal that prompts the pituitary to release growth hormone. Downstream of growth hormone, the liver produces IGF-1 (insulin-like growth factor 1), the mediator through which many of GH's effects are studied. A key concept in the research framing is that CJC-1295 works upstream, at the level of the body's own release machinery, rather than introducing growth hormone directly. In study models this preserves the pituitary's natural pulsatile pattern of secretion — one of the reasons GHRH analogs are of interest to researchers studying the GH axis as a system rather than just flooding it with exogenous hormone. Why it's often paired with a GHRP in research In the literature, GHRH analogs like CJC-1295 are frequently studied alongside a second class of peptides — growth-hormone-releasing peptides (GHRPs) such as ipamorelin. The rationale is mechanistic: GHRH analogs and GHRPs act on two different receptors and two different pathways that both converge on growth hormone release. Studied together, they've been reported to produce a combined effect greater than either alone, because they're pulling two separate levers on the same system. This pairing is a recurring theme in GH-axis research, which is why the two peptides are so often discussed in the same breath. It's a mechanistic observation from study models, not a usage recommendation. What the research has examined Most of the relevant work sits in a few areas: GH and IGF-1 dynamics. The core body of research looks at how GHRH analogs affect growth hormone secretion patterns and downstream IGF-1 levels in animal and clinical pharmacology models. Half-life and pharmacokinetics. A significant share of the CJC-1295 literature is specifically about the DAC modification and how albumin binding extends the molecule's duration — the foundational work that made the peptide notable in the first place. The GH axis as a regulatory system. Because CJC-1295 acts upstream, it's used as a tool for studying how the hypothalamic-pituitary axis regulates growth hormone, rather than only its end effects. As always, the honest framing is that this is characterized pharmacology in research contexts. Claims that leap from "affects GH secretion in a study model" to specific real-world outcomes run ahead of what the data support. Stability, storage, and handling For a research-grade lyophilized peptide, standard handling principles apply: Store the sealed, freeze-dried powder cold and away from light. Lyophilized peptide is dramatically more stable than peptide in solution. Once in solution, refrigerate and treat stability as a matter of weeks, not months. Avoid repeated freeze-thaw cycles, which degrade peptides. Use appropriate diluents. Research handling typically uses bacteriostatic water as the diluent because its preservative supports a longer usable window than sterile water once a vial is opened. Label and date solutions so batches don't get mixed up. These are storage and stability considerations for lab material — not a use protocol. How to evaluate quality CJC-1295 is a peptide where quality varies wildly between suppliers, so this is where your attention pays off: Which version is it? The COA should state clearly whether it's CJC-1295 with DAC or without DAC (mod GRF 1-29). If a listing doesn't specify, that's a red flag. Third-party COA. A legitimate supplier provides a Certificate of Analysis from an independent lab, batch-specific, not an in-house claim. Purity by HPLC, with a stated figure (commonly ≥98%). Identity by mass spectrometry, confirming the correct molecular weight for the specific version. If a supplier can't produce a current, batch-matched COA that names the DAC status, treat the product as unverified. Frequently asked questions What's the difference between CJC-1295 and mod GRF 1-29? "Mod GRF 1-29" is CJC-1295 without the DAC complex. Both are stabilized GHRH analogs; the DAC version lasts far longer by binding to albumin, while the no-DAC version acts in a shorter, more pulse-like way. Why is CJC-1295 studied with ipamorelin? They act on different receptors that both lead to growth hormone release, so in research models the combination produces a larger effect than either peptide on its own. Does CJC-1295 contain growth hormone? No. It's a GHRH analog that acts on the body's own pituitary release machinery — it works upstream, not by adding growth hormone directly. What should I check before buying? A current, third-party COA that names the version (DAC vs no-DAC) and reports HPLC purity and mass-spec identity for the specific batch. Element supplies research-grade materials for laboratory use. Nothing here is medical advice or a recommendation for human use. Browse related research peptides for compounds studied in the same context. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles